Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer

Drugs

Volumn 73, Issue 14, 2013, Pages 1517-1524

  Alva, Ajjai ^a   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYPROTERONE ACETATE; DEGARELIX; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GLUCOCORTICOID RECEPTOR ANTAGONIST; GONADORELIN; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; HISTRELIN; KETOCONAZOLE; LEUPRORELIN; MEDROXYPROGESTERONE; METRONIDAZOLE; NILUTAMIDE; PACLITAXEL; TRIPTORELIN; VENLAFAXINE;

ADRENAL GLAND; ADRENAL INSUFFICIENCY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; ERECTILE DYSFUNCTION; GYNECOMASTIA; HOT FLUSH; HUMAN; LIVER INJURY; MEDLINE; METASTASIS; MUSCLE MASS; ORCHIECTOMY; PATHOLOGIC FRACTURE; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SPINAL CORD COMPRESSION; URINARY TRACT OBSTRUCTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84894682902     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0106-3     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29
2. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97(6):1507-16
3. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 Suppl 1):3-12
4. Scardino PT, Linehan WM, Zelefsky MJ, Vogelzang NJ, Rini BI, Bochner BH, Sheinfeld J, editors. Comprehensive textbook of genitourinary oncology, 4th edn. Lippincott Williams & Wilkins, Philadelphia; 2011
5. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56(6): 1021-4
6. Nyman CR, Andersen JT, Lodding P, Sandin T, Varenhorst E. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy. BJU Int. 2005;96(7):1014-8
7. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165-70
8. Zinner NR, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3. 6 mg and 10. 8 mg: results of a randomized open-label trial. Urology. 2004;64(6):1177-81
9. Sharifi R, Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol. 2002;168(3):1001-4
10. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol. 2006;49(1):54-8 discussion 58
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29
12. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97(6):1507-16
13. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 Suppl 1):3-12
14. Scardino PT, Linehan WM, Zelefsky MJ, Vogelzang NJ, Rini BI, Bochner BH, Sheinfeld J, editors. Comprehensive textbook of genitourinary oncology, 4th edn. Lippincott Williams & Wilkins, Philadelphia; 2011
15. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56(6): 1021-4
16. Nyman CR, Andersen JT, Lodding P, Sandin T, Varenhorst E. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy. BJU Int. 2005;96(7):1014-8
17. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165-70
18. Zinner NR, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3. 6 mg and 10. 8 mg: results of a randomized open-label trial. Urology. 2004;64(6):1177-81
19. Sharifi R, Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol. 2002;168(3):1001-4
20. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol. 2006;49(1):54-8 discussion 58
21. Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2009;12(1):88-93
22. Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol. 2011;185(3):848-54
23. Raddin RS, Walko CM, Whang YE. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. Anticancer Drugs. 2011;22(3):299-302
24. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormonereleasing hormone therapy: prognostic significance? BJU Int. 2010;105(5):648-51
25. Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab. 2009;20(1):43-50
26. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-8
27. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000;355(9214):1491-8
28. Labrie F, Dupont A, Belanger A, et al. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Horm Res. 1983;18(1-3):18-27
29. Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol. 2009;11(2): 52-60
30. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol. 1998;33(2):144-51
31. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Longterm efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol. 1997;158(1):160-3
32. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-42
33. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24): 2029-36
34. Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001;57(4):727-32
35. Tay MH, Kaufman DS, Regan MM, et al. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol. 2004;15(6):974-8
36. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79(2):235-46
37. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314-25
38. Hussain M, Tangen CM, Higano C, et al. Absolute prostatespecific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24(24):3984-90
39. Smith DC, Tangen CM, Jr. Veldhuizen Van PJ, et al. Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. Urology. 2011;77(5):1172-6
40. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008; 26(36):5936-42
41. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149-58
42. Smith MR, Saad F, Egerdie B, et al. Sarcopenia during androgendeprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271-6
43. Pagliarulo V, Bracarda S, Eisenberger MA, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61(1):11-25
44. Kritchevsky SB, Tooze JA, Neiberg RH, et al. 25-Hydroxyvitamin D, parathyroid hormone, and mortality in black and white older adults: the health ABC study. J Clin Endocrinol Metab. 2012;97(11):4156-65
45. Datta M, Schwartz GG. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist. 2012;17(9):1171-9
46. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745-55
47. Lanfrey P, Mottet N, Dagues F, et al. Hot flashes and hormonal treatment of prostate cancer. Prog Urol. 1996;6(1):17-22
48. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11(2): 147-54
49. Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009;20(3):542-9.